Rolf Studer

Allschwil, BL, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

The novel lysophosphatidic acid receptor 1-selective antagonist, ACT-1016-0707, has unique binding properties that translate into effective antifibrotic and anti-inflammatory activity in different models of pulmonary fibrosis.

The novel lysophosphatidic acid receptor 1-selective antagonist, ACT-1016-0707, has unique binding properties that translate into effective antifibrotic and anti-inflammatory activity in different models of pulmonary fibrosis.

Journal: The Journal of pharmacology and experimental therapeutics

Published: June 15, 2024

A uniquely efficacious type of CFTR corrector with complementary mode of action.

A uniquely efficacious type of CFTR corrector with complementary mode of action.

Journal: Science advances

Published: March 01, 2024

NF-κB drives epithelial-mesenchymal mechanisms of lung fibrosis in a translational lung cell model.

NF-κB drives epithelial-mesenchymal mechanisms of lung fibrosis in a translational lung cell model.

Journal: JCI insight

Published: September 03, 2021

GPCR-induced YAP activation sensitizes fibroblasts to profibrotic activity of TGFβ1.

GPCR-induced YAP activation sensitizes fibroblasts to profibrotic activity of TGFβ1.

Journal: PloS one

Published: May 10, 2019

The Antifibrotic Activity of Prostacyclin Receptor Agonism Is Mediated through Inhibition of YAP/TAZ.

The Antifibrotic Activity of Prostacyclin Receptor Agonism Is Mediated through Inhibition of YAP/TAZ.

Journal: American journal of respiratory cell and molecular biology

Published: December 12, 2018

Granulomatous lung inflammation is nanoparticle type-dependent.

Granulomatous lung inflammation is nanoparticle type-dependent.

Journal: Experimental lung research

Published: January 12, 2018

Cenerimod, a novel selective S1P1 receptor modulator with unique signaling properties.

Cenerimod, a novel selective S1P1 receptor modulator with unique signaling properties.

Journal: Pharmacology research & perspectives

Published: August 30, 2017

Serotonin biosynthesis as a predictive marker of serotonin pharmacodynamics and disease-induced dysregulation.

Serotonin biosynthesis as a predictive marker of serotonin pharmacodynamics and disease-induced dysregulation.

Journal: Scientific reports

Published: April 19, 2016

Comparison of Macitentan and Bosentan on Right Ventricular Remodeling in a Rat Model of Non-vasoreactive Pulmonary Hypertension.

Comparison of Macitentan and Bosentan on Right Ventricular Remodeling in a Rat Model of Non-vasoreactive Pulmonary Hypertension.

Journal: Journal of cardiovascular pharmacology

Published: August 01, 2015

FTY720 Phosphate Activates Sphingosine-1-Phosphate Receptor 2 and Selectively Couples to Gα12/13/Rho/ROCK to Induce Myofibroblast Contraction.

FTY720 Phosphate Activates Sphingosine-1-Phosphate Receptor 2 and Selectively Couples to Gα12/13/Rho/ROCK to Induce Myofibroblast Contraction.

Journal: Molecular pharmacology

Published: December 05, 2014

Sphingosine-1-phosphate (S1P) displays sustained S1P1 receptor agonism and signaling through S1P lyase-dependent receptor recycling.

Sphingosine-1-phosphate (S1P) displays sustained S1P1 receptor agonism and signaling through S1P lyase-dependent receptor recycling.

Journal: Cellular signalling

Published: December 20, 2013

Sphingosine 1-phosphate (S1P) receptor agonists mediate pro-fibrotic responses in normal human lung fibroblasts via S1P2 and S1P3 receptors and Smad-independent signaling.

Sphingosine 1-phosphate (S1P) receptor agonists mediate pro-fibrotic responses in normal human lung fibroblasts via S1P2 and S1P3 receptors and Smad-independent signaling.

Journal: The Journal of biological chemistry

Published: April 17, 2013

Showing 1-12 of 14

Last Updated: 09/26/2026